Giant Biogene (02367.HK): Performance Growth and Analyst Optimism Drive Hong Kong Stock Popularity

Giant Biogene (02367.HK) is a leading enterprise in China’s recombinant collagen technology field [0], focusing on functional skincare products, medical dressings, etc., with core brands including Comfy (可复美), Collgene, etc. [0]. Financial data shows that the company’s 2024 revenue increased by 57.2% year-on-year to RMB5.5 billion, and net profit grew by 42.4% [0]; H1 2025 revenue increased by 22.5%, net profit by 20.2% [0], showing strong performance. In terms of market position, it ranks as the third-largest medical aesthetic maintenance enterprise in China [0], benefiting from the growth of online sales in the medical aesthetic industry and the trend of consumer demand upgrading [0].

Regarding analyst ratings, multiple international banks have given positive evaluations: Macquarie maintains an ‘Outperform’ rating with a target price of HK$80 [5]; HSBC Research maintains a ‘Buy’ rating with a target price of HK$81.9 [6]; Citi maintains a ‘Buy’ rating with a target price of HK$55.4 [7]. In addition, the company has been included in the preferred portfolio for the second half of the year by securities firms like CICC, becoming a popular target among new consumer stocks [9].

1. Technical Advantages and Brand Strength
   : Recombinant collagen technology as core competitiveness supports product premium and market share [0]; Comfy brand continues to lead, bringing stable cash flow to the company [0].
2. Growth Potential
   : Plans to enter the medical aesthetic skin filler market through hospital networks to expand business boundaries [0]; optimization of online sales channels (such as live stream recovery) is expected to further drive revenue growth [0].
3. Alignment with Market Trends
   : As a representative of new consumer stocks, it benefits from consumption upgrading and long-term development of the medical aesthetic industry [0].

1. Product Safety Risk
   : There have been historical disputes over ingredients of star products, which may affect brand reputation [8];
2. Intensified Market Competition
   : More participants in the medical aesthetic maintenance field may lead to share dilution [0].

1. Business Expansion
   : Entry into the skin filler market is expected to open up new growth space [0];
2. Capital Attention
   : As a recommended target by securities firms, it is expected to gain more investor attention [9].

Giant Biogene has become a popular target in the Hong Kong stock market due to its strong financial performance, core technical advantages, and positive analyst recommendations. However, investors need to pay attention to potential risks such as product safety and market competition to fully evaluate its investment value.